Asia-Pacific Pharmaceuticals Co., Ltd.

Announcement on Participating in the 2026 Zhejiang Region Listed Companies Online Investor Reception Day and 2025 Annual Performance Briefing

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. announces its participation in the 2026 Zhejiang Region Listed Companies Online Investor Reception Day and 2025 Annual Performance Briefing. The event aims to enhance investor interaction and will be held online on May 13, 2026. Key company executives will discuss the 2025 performance, governance, strategy, and financing plans. Investors are invited to submit questions in advance.

Annual Report for 2025

Guolian Minsheng Securities Investment Banking Co., Ltd. Report on the Fourth Quarter of 2025 and First Quarter of 2026 Continuing Supervision Opinion for Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. Detailed Equity Change Report

This report provides a continuing supervision opinion on the equity change of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. by Guolian Minsheng Securities. It confirms that the acquisition procedures were compliant, disclosures were timely, and the acquirer and the company operated in accordance with regulations. No violations of commitments or significant changes in business plans were found during the supervision period.

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. Independent Director 2025 Annual Performance Report

This report details the performance of Independent Director Lv Haizhou for Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. in 2025. He attended all required meetings, actively participated in discussions, and voted in favor of all proposals, fulfilling his duties diligently. His attendance record and committee participation demonstrate his commitment to overseeing the company's operations and safeguarding shareholder interests.

Independent Director's 2025 Annual Performance Report (Cai Min)

This report details the performance of Independent Director Cai Min for 2025. She attended all required meetings, actively participated in discussions, and exercised independent judgment on company matters. The report confirms her compliance with independence requirements and her commitment to safeguarding shareholder interests, particularly those of minority shareholders.

Independent Director's Annual Work Report for 2025 (Liu Yuehui)

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. Internal Control Audit Report

This report presents the internal control audit of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. for the year ended December 31, 2025. The audit was conducted by Zandar Certified Public Accountants LLP in accordance with relevant standards. The report concludes that the company maintained effective financial reporting internal controls in all material aspects.

2025 Annual Internal Control Self-Evaluation Report

This report evaluates the effectiveness of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd.'s internal control system as of December 31, 2025. The company found no material weaknesses in financial or non-financial reporting internal controls. The report outlines the evaluation scope, methodology, and defect identification standards, confirming the system's overall effectiveness.

Management System for Remuneration of Directors and Senior Management

This document outlines the remuneration management system for directors and senior management of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. It establishes principles for fair and performance-based compensation, including basic salary, performance bonuses, and long-term incentives. The system aims to align compensation with company performance, strategic goals, and market standards, with specific provisions for independent directors and disclosure requirements.

Announcement on Disposal of Part of Non-current Financial Assets

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. announced its board of directors approved the disposal of certain non-current financial assets. This move aims to optimize asset liquidity and structure, not impacting production or operations. The board authorized management to execute the disposal within 12 months, subject to market conditions and risk control. The matter is within the board's authority and does not require shareholder approval.

Announcement on the Purchase of Directors' and Senior Management Liability Insurance

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. announced its decision to purchase directors' and senior management liability insurance. The insurance coverage limit is RMB 50 million, with an annual premium not exceeding RMB 250,000. This measure aims to improve risk management and encourage directors and senior management to perform their duties. The proposal will be submitted to the shareholders' meeting for approval.

Announcement on the Company's Application for Comprehensive Credit Line from Banks

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. announced its board of directors approved applying for a comprehensive credit line of up to RMB 300 million from banks. The credit line will cover various financing needs and will be effective from the 2025 to the 2026 annual general meetings. The proposal requires shareholder approval.

Announcement on Uncovered Losses Reaching One-Third of Paid-in Capital

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. announces that its accumulated uncovered losses have exceeded one-third of its paid-in capital as of December 31, 2025. This situation necessitates a shareholder meeting for review. The losses are primarily attributed to a RMB 1.24 billion investment loss in 2019 and RMB 319 million in asset impairment. The company outlines strategies including sales system reform, R&D investment, and cost control to address the situation.

Announcement on Changes in Accounting Policies

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. announces a change in accounting policies approved by the Board of Directors. This change is in response to new regulations issued by the Ministry of Finance, effective January 1, 2026. The company expects no significant impact on its financial position, results of operations, or cash flows.

Announcement on the Provision for Credit Impairment Losses and Asset Impairment Losses

Announcement on Signing the Supplementary Agreement to the Technology Development Contract and Related Party Transaction

Zhejiang Yatai Pharmaceutical Co., Ltd. announces the signing of a supplementary agreement to a technology development contract for the STC008 project. The company will acquire the project rights from its controlling shareholder, Zhejiang Xinghao Holdings, for RMB 500 million plus an 8% sales commission. This transaction is considered a related party transaction and requires shareholder approval. The STC008 project is currently in Phase I clinical trials, with inherent risks and uncertainties regarding its development and commercialization.

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. Notice of 2025 Annual Shareholders' Meeting

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. announces its 2025 Annual Shareholders' Meeting to be held on May 22, 2026. The meeting will discuss 11 proposals, including the 2025 work report, financial statements, and profit distribution plan. Shareholders can attend in person or vote online.

Announcement on the Resolutions of the Twelfth Meeting of the Eighth Board of Directors

This announcement details the resolutions passed at the twelfth meeting of the eighth Board of Directors of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. Key decisions included approving the 2025 work reports, financial statements, and profit distribution plan, which proposes no cash dividends, stock dividends, or capital reserve increases due to negative undistributed profits. Other resolutions covered accounting policy changes, asset disposal, and the appointment of a new head of internal audit.

Announcement on Proposed Non-Distribution of Profits for 2025

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. announced its 2025 profit distribution plan, proposing no cash dividends, bonus shares, or capital reserve transfers. This decision is due to negative retained earnings in both consolidated and parent company statements, which do not meet cash dividend conditions. The plan aims to ensure normal operations and future development, maintaining long-term shareholder interests.

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. 2026 First Quarter Report

This report details Zhejiang Asia-Pacific Pharmaceutical Co., Ltd.'s financial performance for the first quarter of 2026. Key figures show a decrease in operating revenue and net profit attributable to shareholders. The company also experienced a significant negative change in net cash flow from operating activities. Total assets and owner's equity also saw slight decreases compared to the previous year-end.

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. Special Review Opinion on Revenue Deduction Matters

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. engaged Zandar Certified Public Accountants LLP to conduct a special review of its revenue deduction matters for 2025. The review confirmed that the company's financial information regarding revenue deductions is prepared in accordance with SZSE listing rules. The report is intended for regulatory compliance and should be read alongside the company's annual audit report.

Report on the Evaluation of the Accounting Firm's Performance in 2025

This report evaluates the performance of the accounting firm, Polit-Zhiyuan (Shenzhen) Certified Public Accountants (Special General Partnership), as the company's 2025 auditor. The firm demonstrated professional competence, independence, and timely completion of audit work, issuing a standard unqualified audit report. The company's board of directors and audit committee approved the firm's performance.

Audit Committee's Report on the Performance of the Accounting Firm in 2025 and Fulfillment of Supervisory Responsibilities

This report evaluates the performance of the accounting firm, Polestar Zhiyuan (Shenzhen) Certified Public Accountants (Special General Partnership), in its 2025 audit of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. The Audit Committee reviewed the firm's qualifications, independence, and audit process, finding them satisfactory. The firm issued a standard unqualified audit report, fulfilling its duties in accordance with regulations.

Special Explanation on the Occupation of Funds by Major Shareholders and Other Related Parties of Zhejiang Yatai Pharmaceutical Co., Ltd.

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions for 2025

Board of Directors' Special Opinion on the Self-Inspection of Independent Directors' Independence for 2025

The Board of Directors of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. issued a special opinion on the self-inspection of independent directors' independence for 2025. The opinion confirms that the independent directors meet the requirements of relevant regulations and the company's articles of association regarding independence.

Annual Audit Report for 2025

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. 2025 Annual Report Summary

This report summarizes Zhejiang Asia-Pacific Pharmaceutical's 2025 performance. The company's main business is chemical preparation R&D, production, and sales. Key figures show a revenue decrease of 20.25% and a net profit increase of 181.27%, largely due to the sale of a subsidiary. The company plans to focus on innovative drug development and international market expansion.

Announcement on Using Idle Own Funds for Cash Management

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. will use up to RMB 500 million of idle own funds for cash management to improve fund utilization and increase returns. The funds will be invested in low-risk wealth management products, structured deposits, large-denomination certificates of deposit, and agreement certificates of deposit. This measure will not affect normal operations and aims to maximize shareholder benefits.

Announcement on Independent Directors Obtaining Qualification Certificates

Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. announces that Ms. Sheng Tianqi has obtained her independent director qualification certificate. She was elected as an independent director at the first extraordinary general meeting of shareholders in 2026. Ms. Sheng completed the pre-appointment training required by the Shenzhen Stock Exchange and received the "Listed Company Independent Director Training Certificate".